The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IASLC TTLC 2022 | What to expect at TTLC 2022
Paul Bunn, MD, University of Colorado Cancer Center, Aurora, CO, gives an overview of he is looking forward to at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC22), including updates in tyrosine kinase inhibitors (TKIs), mechanisms of resistance to TKIs, and novel therapies to counter TKI-resistant lung cancer. Prof. Bunn additionally addresses strategies to overcome central nervous system (CNS) metastases, alternative biomarkers to PD-L1, as well as antibody drug conjugates. This interview took place at TTLC 2022.
Disclosures
Paul Bunn, MD is a member of the DMC committee for Merck, and BMS; has received consulting fees from AZ, Lilly, Ascentage, CStone, viecure, and Imidex; and is on the Board of Directors for Verastem.
